Bipolar Disorder Drugs and Treatment Market Report 2026

The bipolar disorder drugs and treatment market size has grown strongly in recent years. It will grow from $8.16 billion in 2025 to $8.63 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to mental health awareness growth, antidepressant usage expansion, psychiatric hospital infrastructure, availability of mood stabilizers, increased diagnosis rates.

The bipolar disorder drugs and treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to precision psychiatry development, long-acting injectable drugs, digital mental health integration, personalized treatment planning, expansion of outpatient psychiatric care. Major trends in the forecast period include increased use of combination drug therapies, rising adoption of long-term mood stabilization, expansion of atypical antipsychotic prescriptions, growing emphasis on relapse prevention, improved treatment adherence programs.

The rising prevalence of mental health disorders is expected to drive the growth of the bipolar disorder drugs and treatment market in the coming years. Mental health disorders are conditions that affect an individual’s thinking, emotions, behavior, or mood, often impairing daily functioning and overall well-being. This increase is largely due to chronic stress from modern lifestyles, as ongoing pressures related to work, finances, and societal expectations can negatively impact emotional health and lead to long-term psychological challenges. Bipolar disorder drugs and treatments play a key role in managing mental health disorders by stabilizing mood fluctuations, improving emotional regulation, and reducing the frequency and severity of disruptive episodes. For example, in 2024, the National Alliance on Mental Illness, a US-based organization, reported that among people aged 18-44 in the U.S., psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations annually. Consequently, the rising prevalence of mental health disorders is fueling the expansion of the bipolar disorder drugs and treatment market.

Leading companies in the bipolar disorder drugs and treatment market are focusing on developing advanced therapies, such as extended-release injectable formulations, to provide consistent and long-term therapeutic effects. Extended-release injectable formulations are designed to gradually release medication into the bloodstream over time, reducing the need for daily dosing and maintaining stable therapeutic levels. For example, in January 2023, Luye Pharma, a China-based pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for Rykindo (risperidone), a long-acting injectable suspension for treating adult schizophrenia and as a stand-alone treatment - or in combination with lithium or valproate - for adult bipolar I disorder. The therapy uses a proprietary microsphere technology developed by Luye Pharma, allowing the intramuscular injection to be administered every two weeks and providing sustained, long-acting effects. The active ingredient, risperidone, is delivered through the extended-release microsphere platform, ensuring a steady release over time.

In April 2025, Johnson & Johnson, a US-based healthcare company, acquired Intra-Cellular Therapies Inc. for an undisclosed amount. Through this acquisition, Johnson & Johnson expanded its portfolio by adding CAPLYTA (lumateperone), a once-daily oral therapy approved for adults with schizophrenia and the first FDA-approved treatment for bipolar depression. The acquisition also included ITI-1284, a promising Phase 2 compound under investigation for generalized anxiety disorder (GAD) and Alzheimer’s disease-related psychosis and agitation. Additionally, the deal strengthens Johnson & Johnson’s clinical pipeline, aligning with its strategic focus on mental health and related therapeutic areas. Intra-Cellular Therapies Inc., based in the US, provides bipolar disorder drugs and treatments.

Major companies operating in the bipolar disorder drugs and treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Sumitomo Pharma America Inc., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Cipla Limited, Gedeon Richter Plc, Lupin Limited, Neurocrine Biosciences Inc., Alkermes Plc.

North America was the largest region in the bipolar disorder drugs and treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder drugs and treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bipolar disorder drugs and treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the bipolar disorder drugs and treatment market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation excipients used in mood stabilizers and antipsychotic medications. These impacts have been most pronounced in second- and third-generation drug segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have faced supply chain disruptions and pricing pressures. However, tariffs have encouraged domestic production of generic psychiatric drugs and localized manufacturing.

The bipolar disorder drugs and treatment market research report is one of a series of new reports that provides bipolar disorder drugs and treatment market statistics, including bipolar disorder drugs and treatment industry global market size, regional shares, competitors with a bipolar disorder drugs and treatment market share, detailed bipolar disorder drugs and treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder drugs and treatment industry. This bipolar disorder drugs and treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bipolar disorder drugs and treatments involve a comprehensive approach aimed at managing extreme mood swings and supporting long-term mental stability. The focus is on regulating brain activity to reduce the intensity and recurrence of mood episodes while addressing related issues such as sleep disturbances, anxiety, or concentration problems.

The main types of bipolar disorder drugs and treatments include mood stabilizers, anticonvulsants, antipsychotics, antidepressants, and anti-anxiety medications. Mood stabilizers help maintain a stable mood, preventing the severe highs (mania) and lows (depression) associated with bipolar disorder. They can be administered orally, parenterally, or via other routes and are used for bipolar I disorder, bipolar II disorder, and cyclothymic disorder. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder drugs and treatment market consists of revenues earned by entities by providing services such as research and development, medical consultation services, mental health counseling support, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The bipolar disorder drugs and treatment market also includes sales of wearable monitoring devices, home diagnostic kits, cognitive assessment devices, and neurostimulation devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.